AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31627728
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.4% ropivacaine (Group T)
Trial: 28902593
Drug: PFO closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFO closure plus long-term antiplatelet therapy
Trial: 28902593
Drug: PFO closure,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFO closure, oral anticoagulation, and antiplatelet therapy
Trial: 25395283
Drug: Figitumumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Figitumumab (20 mg/kg) plus erlotinib (150 mg/day)
Trial: 15004870
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no management or treatment)
Trial: 11520714
Drug: Terbutaline inhalation
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhalation via a pressurized metered-dose inhaler
Trial: 11520714
Drug: Terbutaline inhalation
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhalation
Trial: 11520714
Drug: sRaw bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sRaw bronchodilator response
Trial: 9764456
Drug: Ticlopidine, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine, 250 mg b.d. for 7 days before surgery and continued for 28 days after surgery
Trial: 8154176
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ASA daily
Trial: 8154176
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg ASA daily
Trial: 31701133
Drug: Methylphenidate (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.25 mg/kg)
Trial: 31694699
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy-based program designed to enhance resilience, focusing on emotion regulation through cognitive reappraisal, delivered in four bi-weekly 120-min sessions.
Trial: 31694699
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy-based program.
Trial: 26354104
Drug: Hyoid suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoid suspension type 2 (HS) + radiofrequency treatment of the base of the tongue (RFT TB)
Trial: 19781209
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg b.i.d for 3 days before and after intervention
Trial: 19781209
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no probucol treatment)
Trial: 19781209
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg b.i.d
Trial: 14513873
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg prednisolone/day
Trial: 11751733
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg once daily)
Trial: 8516658
Drug: Cisapride 30
RxNorm normalized name: cisapride 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 30 mg/day
Trial: 8516658
Drug: Metoclopramide 30
RxNorm normalized name: metoclopramide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 30 mg/day
Trial: 8516658
Drug: Domperidone 30
RxNorm normalized name: domperidone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 30 mg/day
Trial: 27880789
Drug: Rumination-Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rumination-Focused Cognitive Behavior Therapy (RFCBT) for 8 weeks
Trial: 25097754
Drug: SUB‐B (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUB‐B (10,000 AUN/ml)
Trial: 25097754
Drug: Stal‐B (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stal‐B (initial phase 10 I.R./ml and maintenance phase 300 I.R./ml)
Trial: 19955506
Drug: Aminophylline 6
RxNorm normalized name: aminophylline 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 6 mg/kg IV, followed by 1.5 mg x kg(‐1) x h(‐1)
Trial: 10442940
Drug: Particulate dentin
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Particulate dentin and plaster of paris combination
Trial: 2151369
Drug: Cyclical use
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate (TAM/HD‐MPA)
Trial: 883328
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (wide local excision and radical mastectomy)
Trial: 10411194
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered trivalent LAIV vaccine
Trial: 7574055
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (preoperative bolus of bupivacaine followed by an infusion of bupivacaine)
Trial: 7574055
Drug: Group MB
RxNorm normalized name: Ionosol-MB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group MB (preoperative bolus of epidural bupivacaine and morphine followed by an infusion of morphine and bupivacaine)
Trial: 7574055
Drug: Group M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group M (preoperative bolus of epidural morphine followed by an infusion of morphine)
Trial: 7574055
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (preoperative bolus of intravenous morphine followed by intravenous patient‐controlled morphine postoperatively)
Trial: 1309127
Drug: Assisted hatching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assisted hatching by zona drilling using acidic Tyrode's solution on embryos with thick zonae (> 15 microns).
Trial: 1309127
Drug: Assisted hatching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assisted hatching by zona drilling using acidic Tyrode's solution on embryos with thin zonae (< 13 microns).
Trial: 6532286
Drug: 1% indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% indomethacin ophthalmic solution
Trial: 25107318
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Therapy‐Primary Care (PST‐PC)
Trial: 21392377
Drug: Five years
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five years of OPUS treatment
Trial: 21392377
Drug: Two years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two years of OPUS treatment
Trial: 11248153
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy plus trastuzumab
Trial: 9579879
Drug: rhEPO (5x500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (5x500 U/kg body weight) + oral Fe2+ (300 mg/day)
Trial: 9579879
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + oral Fe2+ (300 mg/day)
Trial: 7538400
Drug: Prolase II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolase II fiber (cytocare) treatment for BPH
Trial: 6797732
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) ointment, 7.5 mg
Trial: 6797732
Drug: Propranolol (P),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (P), 20-40 mg, 3 times daily
Trial: 6797732
Drug: Nifedipine (N),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (N), 10 mg, 3-4 times daily
Trial: 31870556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pimasertib (60 mg daily) + SAR245409 (70 mg daily)
Trial: 31870556
Drug: Pimasertib alone
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib alone (60 mg BID)
Trial: 31870556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pimasertib + SAR245409
Trial: 21298288
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with Chinese herbal medicine (Kangliuzengxiao decoction during chemotherapy and Feiyanning decoction after chemotherapy)
Trial: 15514373
Drug: LV5FU2 (Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 (Leucovorin 200 mg/m2 + Fluorouracil 400 mg/m2 bolus + Fluorouracil 600 mg/m2 continuous infusion)
Trial: 15514373
Drug: LV5FU2 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 plus cisplatin (50 mg/m2)
Trial: 15514373
Drug: LV5FU2 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 plus irinotecan (180 mg/m2)
Trial: 11694773
Drug: Concurrent schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent schedule of short-infusion IFO at total dose of 7.5-9 g/m² over 5 days plus iv bolus EPI at 90-120 mg/m²/cycle, repeated every 3 weeks (group A)
Trial: 11694773
Drug: Sequential schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential schedule of dose-intense, continuous infusion IFO at a total dose of 14-18 g/m² for 2 cycles followed by bimonthly EPI at 120-160 mg/m²/cycle (group B)
Trial: 762958
Drug: High potassium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High potassium cardioplegic solution (20 mEq. per liter)
Trial: 762958
Drug: Low potassium
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low potassium cardioplegic solution (5 mEq. per liter)
Trial: 31118371
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg repaglinide per day (1 mg each time before meals) for 8 weeks
Trial: 17041001
Drug: Risedronate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 2.5 mg/day (group R)
Trial: 17041001
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of risedronate and alfacalcidol (group R+A)
Trial: 17051709
Drug: Local hyperthermia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local hyperthermia using balloon-type electrodes in combination with standard chemo- and radiotherapy
Trial: 11555746
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation combined with cognitive behavioral therapy
Trial: 31985112
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg nightly for five nights
Trial: 23583817
Drug: PVRV administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV administered intramuscularly (1 ml)
Trial: 23583817
Drug: PVRV administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV administered intradermally (0.1 ml)
Trial: 23583817
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available PVRV (Verorab) administered intramuscularly
Trial: 21958773
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy targeting LDL levels less than 100 mg/dL
Trial: 21958773
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy targeting LDL levels less than 70 mg/dL
Trial: 21958773
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with LDL levels >100 mg/dL
Trial: 16385088
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at 150 to 200 mg per day
Trial: 14666440
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg x kg(‐1) (group midazolam)
Trial: 10971792
Drug: orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orlistat 120 mg three times daily
Trial: 8782006
Drug: Tauroursodeoxycholic acid
RxNorm normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tauroursodeoxycholic acid (10 mg kg‐1)
Trial: 8782006
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (10 mg kg‐1)
Trial: 1616093
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate spray (30 s before induction)
Trial: 1616093
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate spray (90 s before induction)
Trial: 1616093
Drug: Placebo buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo buccal spray (90 s before induction)
Trial: 27430256
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg BID for 12 months
Trial: 17135183
Drug: Ceftriaxone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone administered by 24 h continuous infusion
Trial: 17135183
Drug: Ceftriaxone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone administered by once‐daily intermittent bolus dosing
Trial: 16266472
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg per day)
Trial: 7889440
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) at doses of 80 to 1300 mg (Part 1)
Trial: 7889440
Drug: Chronic dose
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic dose of ASA (325 mg) (Part 2)
Trial: 2228924
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment during double-blind trials
Trial: 657455
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium (100 mEq) with 200ml of 5% dextrose in water intravenously
Trial: 657455
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium (100 mEq) with placebo capsules orally
Trial: 657455
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium (50 mEq) in patients with primary adrenocortical insufficiency
Trial: 657455
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium (50 mEq) in patients with primary adrenocortical insufficiency
Trial: 26037286
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs) in addition to antiplatelet therapy
Trial: 26037286
Drug: PAR-1 antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PAR-1 antagonists in addition to antiplatelet therapy
Trial: 23515265
Drug: Daily median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily median estimated pulmonary artery diastolic pressures (ePAD)
Trial: 21757376
Drug: GIN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIN therapy (high-dose insulin at 5 mU/kg/min during surgery)
Trial: 21757376
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (insulin on a sliding scale aiming at normoglycemia)
Trial: 19539104
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of alendronate sodium 70 mg
Trial: 19539104
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of alendronate sodium 70 mg
Trial: 9989882
Drug: Peripheral blood
RxNorm normalized name: Peripheral blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood stem cell (PBSC) collection with mobilising chemotherapy (cyclophosphamide, etoposide, doxorubicin, cytosine arabinoside) and G-CSF, total of 47 courses.
Trial: 9989882
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autologous stem cell rescue (21 of 37 patients).
Trial: 2741191
Drug: Clindamycin 900
RxNorm normalized name: clindamycin 900 MG in 6 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 900 mg every 8 h admixed with gentamicin 1.5 mg/kg every 8 h (8-h group)
Trial: 2741191
Drug: Clindamycin 600
RxNorm normalized name: clindamycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 600 mg every 6 h given separately (6-h group)
Trial: 31567873
Drug: 50 mg/d
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/d PhytoSERM for 12 weeks
Trial: 31567873
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d PhytoSERM
Trial: 30636738
Drug: Idalopirdine 60
RxNorm normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idalopirdine 60 mg/day as adjunctive therapy
Trial: 30636738
Drug: Idalopirdine 60
RxNorm normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idalopirdine 60 mg/day as adjunctive therapy with memantine
Trial: 30636738
Drug: Idalopirdine 60
RxNorm normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idalopirdine 60 mg/day
Trial: 30636738
Drug: Idalopirdine 60
RxNorm normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idalopirdine 60 mg/day with memantine
Trial: 21255982
Drug: Haloperidol, mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol, mean dosage 4.14 mg (±1.70), duration 42.92 days (±16.85)
Trial: 21255982
Drug: Risperidone, mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone, mean dosage 4.17 mg (±1.55), duration 42.92 days (±16.85)
Trial: 11180021
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of mycophenolate mofetil alone (study 1)
Trial: 11180021
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of mycophenolate mofetil and 2 tablets of iron ion preparations (study 2)
Trial: 3100007
Drug: Diltiazem (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (all doses)
Trial: 3100007
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg (challenge after treatment)
Trial: 3100007
Drug: Diltiazem (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (sustained therapy)
Trial: 27160475
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus goserelin (10.8 mg goserelin by subcutaneous injection on the first day of irradiation and 3 months later)
Trial: 17990049
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg per day (one patient received just 5 mg)
Trial: 1752498
Drug: Concentrated 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated 25% albumin infusion for the first 16 hours after surgery
Trial: 1752498
Drug: Concentrated 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated 25% albumin infusion
Trial: 1752498
Drug: Standard crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard crystalloid solution
Trial: 7043498
Drug: Pimozide (40‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (40‐60 mg/day)
Trial: 7043498
Drug: Haloperidol (40‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (40‐60 mg/day)
Trial: 26845265
Drug: Lithium and
RxNorm normalized name: Lithium and/or lithium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium and Quetiapine (both with adjunctive personalized treatments)
Trial: 17698900
Drug: vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin (100 mg) with glibenclamide (5 mg)